Cite
HARVARD Citation
Shimizu, M. et al. (2019). Evaluation of the effects of dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non‐alcoholic fatty liver disease. Diabetes, obesity & metabolism. 21 (2), pp. 285-292. [Online].